Current stock page

Catalysts

LGND Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

LGNDLigand Pharmaceuticals Incorporated

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$308.79−$7.48 (−2.37%)

Latest quote

  • Momentum
    86
  • Value
    61
  • Quality
    76
  • Risk resilience
    70
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 25, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 76/100

Momentum 86/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 23.99%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 86/100AIQ Edge 10/10 Sector Leader
Beat rate
75%
6 of 8 reported periods
Average surprise
-10.1%
Across covered historical reports
Latest result
+14.6%
Oct 29, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Oct 29, 2026—$2.33$2.67+14.6%$77M$78.75M
Aug 6, 2026—$2.01$2.37+17.9%$61.3M$63.69M
May 14, 2026—$1.84$1.63-11.4%$59.1M$51.72M
Feb 26, 2026—$1.46$2.02+38.4%$55.59M$59.67M
Nov 6, 2025—$1.97$3.09+56.9%$58.74M$115.46M
Aug 7, 2025—$1.42$1.60+12.7%$43.87M$47.63M
May 8, 2025—$1.21$1.33+9.9%$38.71M$45.33M
Feb 27, 2025—$1.37-$1.64-219.7%$39.03M$42.81M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
11
Buy
12-month analyst target
$367.00
+18.85% versus current price
Based on 11 analyst observations. Targets are estimates, not predictions.
Low target
$345.00
+11.73% vs latest price
Average target
$367.00
+18.85% vs latest price
High target
$406.00
+31.48% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 25, 2027

Next known earnings or reporting date.

EPS estimate$2.84

Current analyst expectation for the upcoming report.

Revenue estimate$97.8M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score86

Where event reaction would show up first.

AIQ score76/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
11
Average target
$367.00
Target upside
18.85%
Target range
$345.00 - $406.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
seekingalpha.com · Oct 30, 2026

Ligand Pharmaceuticals Incorporated 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:LGND) 2026-10-30

2026-10-30. The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with their 2026 Q3 earnings call.

seekingalpha.com · Oct 30, 2026

Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDTCompany ParticipantsMelanie Herman - Executive Director of...

insidermonkey.com · Sep 27, 2026

Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers.

manilatimes.net · Sep 22, 2026

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients

manilatimes.net · Aug 26, 2026

Ligand to Participate in September Investor Conferences

JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences:

Open full news and sentiment

LGND Catalysts FAQ

What are the next catalysts for LGND stock?

LGND's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move LGND stock?

Upcoming events that could move LGND include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could LGND's next earnings report affect the stock?

LGND's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive LGND stock higher?

LGND could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt LGND stock?

LGND could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.